EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 328 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide Aiming to Support Cancer Research, ESMO Calls on the European Council to Allocate a Budget of at Least €220 Billion to Horizon Europe MOST POPULAR Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown October 20, 2020 PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... February 9, 2026 5-Yr-Old Cancer Survivor Used His Birthday To Collect Toys For Sick... October 15, 2019 Reunión anual de la American Society of Clinical Oncology de 2021:... June 3, 2021 Load more HOT NEWS Cancer Research UK appoints new Trustees and independent Committee Members The Winter Solstice Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H... Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially...
